and serves as an adhesion factor for many of the same cells [5, . Our studies have shown a direct relationship between TSP synthesis and TSP binding among squamous epithelial cells [5, 7, lo-121 . This provides a mechanism whereby the endogenously synthesized TSP may be used in an autocrine fashion to promote cell-substrate adhesion. In epithelial cells, TSP synthesis is related to the growth cycle. Rapidly proliferating, undifferentiated cells synthesize large amounts of TSP while synthesis is decreased greatly during differentiation [5, lo] . This is consistent with the suggestion that TSP has an important function in epithelial growth. In support of this is the finding that TSP is localized in uivo to sites where epithelial cells are rapidly proliferating (i.e., in the basal cell layer of skin and around hair follicles) [ 131. A direct role for TSP in smooth muscle cell proliferation [ 14, 151 and fibroblast proliferation has also been shown [16] .
Past studies have demonstrated that monocytes synthesize TSP in culture [ 17,181. However, monocytes do not actively proliferate in culture and the relationship between TSP synthesis and monocyte function is unknown. To address this question, we have utilized the monocyte-like line U937. This cell line was originally derived from a histiocytic lymphoma and expresses many of the characteristics of monocytes [19] . U937 cells can be induced by a variety of agents to differentiate into cells with characteristics of mature macrophages [20] . We report here that U937 cells produce small amounts of TSP when unstimulated but synthesize greatly increased amounts of TSP after treatment with phorbol esters. Concomitant with this is up-regulation of adhesion to TSP as well as to vascular endothelial cells of rat origin. That TSP produced by U937 cells may contribute to their adhesion to endothelial cells is suggested by the finding that antibodies to TSP partially inhibit adhesion to endothelial cell monolayers.
MATERIALS AND METHODS

U937 cells.
A 
RESULTS
TSPproduction by control and PMA-stimulated U937 cells. In the first series of experiments control U937 cells and U937 cells incubated for 1 day with 100 nM PMA in growth medium were examined for TSP production, secretion, and cell surface expression. Results from biosynthetic labeling/immunoprecipitation studies are shown in Fig. 1 No detectable band corresponding to intact TSP (i.e., at 160-170 kDa under reducing conditions) was seen. The presence of moieties at 120 and 70 kDa is consistent with proteolysis of intact TSP. TSP is a proteolytically sensitive molecule and fragments of I20 and 70 kDa are the major products seen after limited proteolysis [lo] .
Extracts from control and PMA-stimulated U937 cells were also immunoprecipitated with rabbit polyclonal anti-fibronectin.
There was no detectable band in the 220-to 240-kDa region of the gel prepared with control cell extract or with extract from PMA-treated cells 1 day after treatment (not shown). ELISAs were used to confirm the increased release of anti-TSP reactive moieties from PMA-treated U937 cells. For these experiments, U937 cells were cultured for 1 day in growth medium with or without PMA. Following this, they were washed and incubated for 18 h in RPMI-BSA.
These culture fluids were then harvested and assayed for TSP and fibronectin by ELISA. The amount, of TSP detected in the culture fluid from the PMA-treated cells was much higher than the amount detected in the control culture fluid (Table 1 ). In contrast, there was no measurable amount of fibronectin in the culture fluid from either control or PMA-treated Indirect immunofluorescence studies with anti-TSP were carried out to determine if there was also increased cell surface TSP expression following PMA treatment. Anti-TSP-stained control cells and cells treated for 1 day with PMA are shown in Fig. 2 . There was significantly more staining of the treated cells than control cells. This was not seen when normal rabbit serum or anti-fibronectin was used in place of anti-TSP (not shown).
U937 cell adhesion to purified extracellular matrix components.
Control and PMA-treated U937 cells were examined for attachment to immobilized TSP, fibronectin, and laminin. A small percentage of untreated cells attached to fibronectin but virtually none attached to TSP or laminin (Fig. 3) . One day after treatment with 100 nM PMA, the U937 cells demonstrated dramatically increased attachment to both TSP and fibronectin (Fig. 3) . In the case of fibronectin, a significant percentage (20-30%) of the attached cells also spread. There was no spreading on TSP and the cells formed large clumps on this substrate (not shown). In contrast to the results with TSP and fibronectin, PMA-treated U937 cells did not attach on laminin (Fig. 3) . The adhesion response to TSP was specific in that pretreatment of the substrate with 50 /*g of rabbit polyclonal anti-TSP completely inhibited the interaction. The same antibody had no effect on cell attachment to fibronectin while rabbit polyclonal anti-fibronectin did not interfere with the attachment to TSP. We were also unable to block adhesion to TSP with commercially available OKM-5 monoclonal antibody (incubated with the cells for 15 min prior to addition of the cells to the substrate).
U937 cell adhesion to endothelial cells. Control and PMA-stimulated U937 cells were examined for adhesion to rat pulmonary artery endothelial cells. Very few of the untreated U937 cells (between 4-18%, depending on the experiment) attached to the endothelial cells. In contrast, a large percentage of the PMA-stimulated U937 cells attached to the endothelial cell monolayers. Attachment was seen as early as 30 min after plating and was maximal by 4 h. In order to determine if TSP plays a role in U937 cell adhesion to endothelial cells, mouse monoclonal antibodies to TSP were used in blocking experiments. For these experiments, control and PMA-treated U937 cells were harvested from culture, washed, and incubated with the appropriate antibody for 15 min in assay buffer (MEM-BSA). The cells along with the antibodies were then added to the endothelial cell monolayers and the assay carried out in the normal manner. The monoclonal antibody to TSP significantly inhibited attachment of PMA-treated U937 cells as compared to the negative control antibody (Table 2). However, anti-TSP proved to be much less effective than the antibody directed against CD18 (Table 2) . DISCUSSION TSP production by monocytes has been examined in two previous studies. In the first, Jaffe et al. [17] demonstrated that human peripheral blood monocytes and mouse resident peritoneal macrophages synthesized TSP and secreted the synthesized moiety into the culture medium. Most of the secreted TSP appeared to be intact, as indicated by autoradiography of biosynthetitally labeled/immunoprecipitated extracts. It was reported in this study that TSP could not be detected on the cell surface or in the cell layer by immunofluorescence. In a later study we also showed that human monocytes synthesize TSP and secrete the intact molecule into the culture medium [18] . Consistent with the observations of Jaffe et al. [ 171, we did not see cell surface TSP by immunofluorescence when the cells were examined immediately after plating. However, when the cells were examined after they had been in culture for 18 h cell surface staining for TSP was clearly evident. Our study also suggested that TSP may serve in the interaction of human peripheral blood monocytes with human squamous carcinoma cells. This was based on the observation that antibodies to TSP partially inhibited monocyte killing of human squamous carcinoma cells and on the observation that squamous epithelial cells which expressed high levels of TSP receptors were more sensitive to killing by monocytes than cells which did not [18] .
In the present study we examined TSP production and cell surface expression by U937 cells. The U937 line was originally derived from a histiocytic lymphoma and demonstrates characteristics of monocytes [19] . U937 cells can be induced by a variety of agents, including PMA, to differentiate into mature macrophage-like cells [20] . Consistent with previous findings with human peripheral blood monocytes, which did not express surface TSP immediately upon isolation but which did after incubation in vitro for 18 h [17, 181, unstimulated U937 cells were deficient in surface TSP but stained brightly with anti-TSP after treatment with PMA. With both normal peripheral blood monocytes and U937 cells, therefore, TSP expression is correlated with cellsubstrate adhesion in vitro. It should be noted that mouse resident peritoneal macrophages have also been shown to synthesize TSP [17] . Thus, TSP production appears to reflect transition from the monocytoid state to macrophage-like cells.
In addition to stimulating TSP biosynthesis, PMA treatment of U937 cells also resulted in increased adhesion to TSP. This suggests that TSP receptor expression is up-regulated concomitantly with induction of TSP synthesis. Coordinated induction of TSP biosynthesis and TSP binding is not unique to these cells. The induction of TSP synthesis in squamous epithelial cells is also accompanied by increased TSP binding and increased cell-substrate adhesion [ll, 121. Additionally, past studies have shown that with other extracellular matrix molecules such as fibronectin, induction of ligand synthesis is accompanied by up-regulation of receptor expression [30-321. Thus, coregulation of extracellular matrix synthesis and expression of their cell surface receptors may be a common occurance. At present, the nature of the TSP-binding moieties up-regulated on the U937 cells by PMA is not known. At least one moiety which has been reported to serve as a TSP receptor on monocytes (i.e., CD36, the antigen for commercially available OKM5 monoclonal antibody) [33] is also expressed on U937 cells [33] and has been reported to be up-regulated following PMA treatment [34] . Perhaps increased expression of this moiety accounts for the increased adhesiveness that follows PMA treatment. We were unable, however, to demonstrate significant inhibition with antibody directed against this ligand and several additional TSP-binding moieties have been identified on other cells. Among these are a member of the integrin family [35] , a heparan sulfate proteoglycan [ 361, and a glycolipid [ 371. Additional studies will be necessary to determine if any of these structures are also influenced by PMA and if any of these receptors are critical to I7937 cell adhesive functions.
A goal of this work was to determine if TSP plays a role in U937 cell adhesion to endothelial cells. Previous studies have shown a role for TSP in monocyte-platelet interaction [34] and our recent study suggested that TSP may be involved in monocyte killing of human squamous carcinoma cells [ 181. In the present study we used a murine monoclonal antibody to TSP to block adhesion to rat pulmonary artery endothelial cells. Attachment of PMA-activated U937 cells to endothelial cells in the presence of this antibody was reduced by approximately 25%. These data suggest that TSP contributes to but is not the major surface ligand mediating adhesion of activated U937 cells to the endothelium. In the same series of experiments as those described above, we found that antibodies to TSP also inhibited human peripheral blood monocyte adhesion to the rat pulmonary artery endothelial cells by approximately 
